Comparison of midcycle BMB findings reported in large studies after intensive chemotherapy induction, compared with current study
| Study . | Type of study . | Patient population . | Induction regimen . | Midcycle BMB results . | Median blast count in midcycle BMB . |
|---|---|---|---|---|---|
| Kern et al22 | Prospective, multicenter (AMLCG 1992 trial) | Ages >16, all AML subtypes (excluding secondary AML) | TAC (includes 7+3+thioguanine) | 47% (213/449) had <5% blasts | 5% |
| Bertoli et al23 | Prospective, multicenter (LAM-2001 trial) | Ages 17-61, all AML subtypes | 7+3 (Ida or dauno) | 68.6% (545/795) had <5% blasts | 9.3% |
| Röllig et al24 | Prospective, multicenter (SAL Dauno-Double trial) | Ages 18-65, all AML subtypes | 7+3 | 45% (389/864) had <5% blasts | Not reported |
| Ofran et al25 | Prospective, multicenter | Ages 20-81, all AML subtypes | 7+3 (14% with addition of clofarabine) | 61.2% (60/98) had <10% blasts + hypocellularity | Not reported |
| Current study | Retrospective, single center | AML with IDH2-R140 mutation | Table 1 (majority 7+3) | 58% (15/26) had ≤5% blasts | 5% |
| AML with IDH2-R172 mutation | 0 (0/15) had ≤5% blasts | 70% |
| Study . | Type of study . | Patient population . | Induction regimen . | Midcycle BMB results . | Median blast count in midcycle BMB . |
|---|---|---|---|---|---|
| Kern et al22 | Prospective, multicenter (AMLCG 1992 trial) | Ages >16, all AML subtypes (excluding secondary AML) | TAC (includes 7+3+thioguanine) | 47% (213/449) had <5% blasts | 5% |
| Bertoli et al23 | Prospective, multicenter (LAM-2001 trial) | Ages 17-61, all AML subtypes | 7+3 (Ida or dauno) | 68.6% (545/795) had <5% blasts | 9.3% |
| Röllig et al24 | Prospective, multicenter (SAL Dauno-Double trial) | Ages 18-65, all AML subtypes | 7+3 | 45% (389/864) had <5% blasts | Not reported |
| Ofran et al25 | Prospective, multicenter | Ages 20-81, all AML subtypes | 7+3 (14% with addition of clofarabine) | 61.2% (60/98) had <10% blasts + hypocellularity | Not reported |
| Current study | Retrospective, single center | AML with IDH2-R140 mutation | Table 1 (majority 7+3) | 58% (15/26) had ≤5% blasts | 5% |
| AML with IDH2-R172 mutation | 0 (0/15) had ≤5% blasts | 70% |
7+3, induction protocol with anthracycline (generally daunorubicin 60 mg/m2, some with 90 mg/m2 or with idarubicin); AMLCG, German AML Cooperative Group; dauno, daunorubicin; Ida, idarubicin; LAM, Leucémie Aiguë Myéloïde; SAL, Study Alliance Leukemia.